日本口腔診断学会雑誌
Online ISSN : 2188-2843
Print ISSN : 0914-9694
ISSN-L : 0914-9694
原著
骨粗鬆症患者における骨吸収抑制薬関連顎骨壊死の臨床的検討
小松 祐子宮本 郁也大橋 祐生角田 直子小野寺 慧川井 忠山谷 元気山田 浩之
著者情報
ジャーナル フリー

2021 年 34 巻 3 号 p. 194-201

詳細
抄録
Objective:This study evaluated clinical conditions, methods and results of treatment for anti-resorptive agents-related osteonecrosis of the jaw (ARONJ) in patients with osteoporosis.
Patients and Methods:Among 62 patients diagnosed with ARONJ in our clinic during the period from January 2012 to December 2016, 32 patients with osteoporosis who were receiving bisphosphonate or denosumab were enrolled in this study. Stage classification at the time of the first visit, cause of onset, methods, and results of treatment were examined in the enrolled patients. Stage classification was divided into four groups of stage 0 to 3. Treatment and outcome were assessed for each stage.
Results:Eight (25%) patients had ARONJ stage 1, 16 (50%) had stage 2, and 8 (25%) had stage 3. Stage 1 patients received conservative therapy: 50% demonstrated success; moreover, 100% of surgically treated patients demonstrated success. Stage 2 patients received conservative therapy: 33.3% demonstrated success; moreover, 75% of surgically treated patients demonstrated success. Stage 3 patients, who received conservative therapy, demonstrated failure. 100% of stage 3 patients demonstrated success after undergoing surgery.
Conclusion:Surgical treatment is useful for ARONJ in patients with osteoporosis for whom conservative therapy was not successful.
著者関連情報
© 2021 日本口腔診断学会
前の記事 次の記事
feedback
Top